Companies in #Lung Nodule Risk Assessment

Biodesix is a Louisville, Colorado-based diagnostic solutions company selling blood-based lung tests that help physicians reclassify the risk of malignancy in suspicious lung nodules and guide treatment decisions. Its commercial portfolio includes the Nodify XL2 and Nodify CDT tests, marketed together as Nodify Lung Nodule Risk Assessment, and the GeneStrat and VeriStrat tests sold as part of its IQLung strategy; it also runs a development services business providing biomarker discovery, assay validation and clinical trial testing for biopharma partners. The company reported third-quarter 2026 revenue of $24.0 million, up 10% year over year on test volume growth of 24% to about 19,400 tests and an 81% gross margin, and cut full-year 2026 revenue guidance to $101 million to $103 million after sales-force turnover and project timing weighed on growth. Biodesix ended the quarter with $28.4 million of cash and roughly 110 sales representatives in the field.